Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Alector Inc (ALEC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Alector's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.34 +0.06    +1.14%
02/05 - Closed. Currency in USD ( Disclaimer )
After Hours
5.39
+0.05
+0.94%
21:46:12 - Real-time Data
  • Volume: 443,057
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 5.19 - 5.41
Type:  Equity
Market:  United States
Alector 5.34 +0.06 +1.14%

Alector Company Profile

 
Read the Alector Inc company profile to learn more about the business and the management team. View Alector Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

246

Equity Type

ORD

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Contact Information

Address 131 Oyster Point Boulevard Suite 600
South San Francisco, 94080
United States
Phone 415 231 5660
Fax -

Top Executives

Name Age Since Title
Arnon Rosenthal 67 2013 Co-Founder, CEO & Director
David M. Wehner 54 2018 Independent Director
Kristine Yaffe 60 2019 Independent Director
Elizabeth A. Garofalo 65 2021 Independent Director
Louis J. Lavigne 74 2018 Independent Chairperson of the Board
Richard H. Scheller 71 2018 Director & Member of Scientific Advisory Board
Stephen L. Hauser - - Member of Scientific Advisory Board
Adam L. Boxer - - Member of Scientific Advisory Board
Michael Heneka - - Member of Scientific Advisory Board
Paula T. Hammond 59 2020 Independent Director
Martin Kampmann - 2022 Member of Scientific Advisory Board
Thomas Christian Sudhof 69 - Member of Scientific Advisory Board
Errol De Souza - 2024 Independent Director
Mark Altmeyer 63 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALEC Price Commentary

Write your thoughts about Alector Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email